Skip to content
Screener

Xencor XNCR EPS (Diluted)

EPS (Diluted) at other companies

Amgen logo
AmgenAMGN
$4.37+64.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$0.35+36.4%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$0.18-50.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$0.18-20.0%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+210%
Enterprise value$1.67B+150%
P/S14.7×+11.3×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss including noncontrolling interest(21,729)(30,825)(150,645)(79,457)
Net loss attributable to noncontrolling interest(214)
Net loss attributable to Xencor, Inc.$(21,729)$(30,825)$(150,645)$(79,243)
Net loss per share attributable to Xencor, Inc. (basic and diluted)$(0.29)$(0.41)$(1.99)$(1.07)
Weighted-average shares used in calculating net loss per share (basic and diluted)75,85974,27975,55573,975
Other comprehensive income (loss), net of tax:
Net unrealized (loss) gain on marketable debt securities(899)(97)(2,448)921
Comprehensive loss$(22,628)$(30,922)$(153,093)$(78,536)

Item 1. Financial Statements

FAQ

What is Xencor's EPS (diluted)?
Xencor (XNCR) reported EPS (diluted) of -$0.29 in Q2 2026.
How has Xencor's EPS (diluted) changed year-over-year?
Xencor's EPS (diluted) increased by 29.3% year-over-year, from -$0.41 to -$0.29.
What is the long-term trend for Xencor's EPS (diluted)?
Over 4 years (2021 to 2025), Xencor's EPS (diluted) has grown at a -2.1% compound annual growth rate (CAGR), from $1.35 to -$1.24.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Xencor's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude